Latest Comments

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Hemophilia gene therapies impress, but pricing doubts remain

Hemophilia gene therapies impress, but pricing doubts remain

Nestling in: food giant makes its mark on the healthcare industry

Nestling in: food giant makes its mark on the healthcare industry

Merck’s Keytruda stumbles in multiple myeloma

Merck’s Keytruda stumbles in multiple myeloma

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

Samsung Bioepis emerging as strong player in the Autoimmune space

Samsung Bioepis emerging as strong player in the Autoimmune space

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: New Hope for Multiple Myeloma Patients

EHA 2017: New Hope for Multiple Myeloma Patients

EULAR 2017: Considerations after first TNF-failure in RA

EULAR 2017: Considerations after first TNF-failure in RA

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

The anti-vaccination movement and public health

The anti-vaccination movement and public health

Brexit: new alliance hopes to ensure healthcare stability in an uncertain future

Brexit: new alliance hopes to ensure healthcare stability in an uncertain future

Niche is the new normal: the growth of the orphan drugs market

Niche is the new normal: the growth of the orphan drugs market

NeuPSIG 2017: cell therapies may hold the key to opioid use in neuropathic pain

NeuPSIG 2017: cell therapies may hold the key to opioid use in neuropathic pain

NeuPSIG 2017: personalized treatments may hold the key to treatment progress in neuropathic pain

NeuPSIG 2017: personalized treatments may hold the key to treatment progress in neuropathic pain

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Big pharma dives back into the lupus pipeline

EULAR 2017: Osteoarthritis pipeline product shows promise

EULAR 2017: Osteoarthritis pipeline product shows promise

DEVOTE trial update: ultra long-acting Insulin Tresiba as safe as insulin glargine

DEVOTE trial update: ultra long-acting Insulin Tresiba as safe as insulin glargine

Chemo-free triplet regimens on the horizon for CLL

Chemo-free triplet regimens on the horizon for CLL